AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of$0.52 on a GAAP basis, reflecting a decrease of 32.5%. Adjusted diluted EPS for the quarter reached $2.97, up 12.1%. ...